Literature DB >> 16371410

The clinical spectrum of neuralgic amyotrophy in 246 cases.

Nens van Alfen1, Baziel G M van Engelen.   

Abstract

We investigated the symptoms, course and prognosis of neuralgic amyotrophy (NA) in a large group of patients with idiopathic neuralgic amyotrophy (INA, n = 199) and hereditary neuralgic amyotrophy (HNA, n = 47) to gain more insight into the broad clinical spectrum of the disorder. Several findings from earlier smaller-scale studies were tested, and for the first time the potential differences between the hereditary and idiopathic phenotypes and between males and females were explored. Generally, the course of the pain manifests itself in three consecutive phases with an initial severe, continuous pain lasting for approximately 4 weeks on average. Sensory involvement was quite common and found in 78.4% of patients but was clinically less impairing than the initial pain and subsequent paresis. As a typically patchy disorder NA can affect almost any nerve in the brachial plexus, although damage in the upper and middle trunk distribution with involvement of the long thoracic and/or suprascapular nerve occurred most frequently (71.1%). We found no correlation between the distribution of motor and sensory symptoms. In INA recurrent attacks were found in 26.1% of the patients during an average 6 year follow-up. HNA patients had an earlier onset (28.4 versus 41.3 years), more attacks (mean 3.5 versus 1.5) and more frequent involvement of nerves outside the brachial plexus (55.8 versus 17.3%) than INA patients, and a more severe maximum paresis, with a subsequent poorer functional outcome. In males the initial pain tended to last longer than it did in females (45 versus 23 days). In females the middle or lower parts of the brachial plexus were involved more frequently (23.1 versus 10.5% in males), and their functional outcome was worse. Overall recovery was less favourable than usually assumed, with persisting pain and paresis in approximately two-thirds of the patients who were followed for 3 years or more.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16371410     DOI: 10.1093/brain/awh722

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  83 in total

Review 1.  Inherited neuropathies: clinical overview and update.

Authors:  Christopher J Klein; Xiaohui Duan; Michael E Shy
Journal:  Muscle Nerve       Date:  2013-06-26       Impact factor: 3.217

2.  Herpes zoster increased risk of neuralgic amyotrophy: a retrospective, population-based matched cohort study.

Authors:  Tsung-Yen Ho; Chi-Hsiang Chung; Yu-Ping Shen; Liang-Cheng Chen; Wu-Chien Chien; Yung-Tsan Wu
Journal:  J Neurovirol       Date:  2018-11-05       Impact factor: 2.643

3.  [Differential diagnosis of neuralgic amyotrophy and vertebral artery dissection].

Authors:  A Wöller; K Plenagl; R Ilg; H Stimmer; M Mühlau
Journal:  Nervenarzt       Date:  2008-02       Impact factor: 1.214

4.  Acute brachial neuritis with central pontine and extrapontine myelinolysis in a renal transplant recipient.

Authors:  Aysu Sen; Aysun Soysal; Ali Sever; Baki Arpaci
Journal:  Neurol Sci       Date:  2013-07-03       Impact factor: 3.307

5.  Neuralgic amyotrophy and hepatitis E virus infection.

Authors:  Jeroen J J van Eijk; Richie G Madden; Annemiek A van der Eijk; Jeremy G Hunter; Johan H J Reimerink; Richard P Bendall; Suzan D Pas; Vic Ellis; Nens van Alfen; Laura Beynon; Lucy Southwell; Brendan McLean; Bart C Jacobs; Baziel G M van Engelen; Harry R Dalton
Journal:  Neurology       Date:  2014-01-08       Impact factor: 9.910

6.  Neuroradiologic and neurophysiologic findings of neuralgic amyotrophy.

Authors:  Dong-Kun Yu; Yong-Jun Cho; Dong-Hwa Heo; Myung Sun Hong; Se-Hyuck Park
Journal:  J Korean Neurosurg Soc       Date:  2010-11-30

7.  Nosology of idiopathic phrenic neuropathies.

Authors:  Simon Podnar
Journal:  J Neurol       Date:  2014-12-06       Impact factor: 4.849

8.  A rare case of pure sensitive Parsonage-Turner syndrome.

Authors:  Maria Elena Pessa; Lorenzo Verriello; Mariarosaria Valente; Gian Luigi Gigli
Journal:  Neurol Sci       Date:  2019-02-07       Impact factor: 3.307

9.  Neuralgic amyotrophy.

Authors:  Lenay Santana; Amparo Gutierrez
Journal:  Curr Treat Options Neurol       Date:  2009-03       Impact factor: 3.598

Review 10.  The neuralgic amyotrophy consultation.

Authors:  Nens van Alfen
Journal:  J Neurol       Date:  2007-04-20       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.